216 related articles for article (PubMed ID: 28030849)
1. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.
Björner S; Rosendahl AH; Simonsson M; Markkula A; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Oncotarget; 2017 Feb; 8(6):9093-9107. PubMed ID: 28030849
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
Ochnik AM; Baxter RC
BMC Cancer; 2017 Dec; 17(1):820. PubMed ID: 29207959
[TBL] [Abstract][Full Text] [Related]
3. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
Chan JY; Hackel BJ; Yee D
Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
[TBL] [Abstract][Full Text] [Related]
4. Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.
Björner S; Rosendahl AH; Simonsson M; Markkula A; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Front Endocrinol (Lausanne); 2017; 8():332. PubMed ID: 29234306
[TBL] [Abstract][Full Text] [Related]
5. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
6. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
7. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
Chan JY; LaPara K; Yee D
Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
[TBL] [Abstract][Full Text] [Related]
8. High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort.
Elebro K; Borgquist S; Rosendahl AH; Markkula A; Simonsson M; Jirström K; Rose C; Ingvar C; Jernström H
Clin Cancer Res; 2017 Feb; 23(3):766-777. PubMed ID: 27810901
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
[TBL] [Abstract][Full Text] [Related]
12. Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors.
Chen J; Nagle AM; Wang YF; Boone DN; Lee AV
J Biol Chem; 2018 Mar; 293(10):3700-3709. PubMed ID: 29330302
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
14. Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment.
Björner S; Rosendahl AH; Tryggvadottir H; Simonsson M; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Front Endocrinol (Lausanne); 2018; 9():306. PubMed ID: 29928262
[TBL] [Abstract][Full Text] [Related]
15. Expression of GRK2 and IGF1R in hepatocellular carcinoma: clinicopathological and prognostic significance.
Lin SB; Zhou L; Liang ZY; Zhou WX; Jin Y
J Clin Pathol; 2017 Sep; 70(9):754-759. PubMed ID: 28202495
[TBL] [Abstract][Full Text] [Related]
16. The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.
Engels CC; de Glas NA; Sajet A; Bastiaannet E; Smit VT; Kuppen PJ; Seynaeve C; van de Velde CJ; Liefers GJ
Mol Oncol; 2016 Apr; 10(4):509-16. PubMed ID: 26706833
[TBL] [Abstract][Full Text] [Related]
17. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
18. The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
Bronsveld HK; De Bruin ML; Wesseling J; Sanders J; Hofland I; Jensen V; Bazelier MT; Ter Braak B; de Boer A; Vestergaard P; Schmidt MK
BMC Cancer; 2018 Feb; 18(1):224. PubMed ID: 29486734
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
20. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
